Paper Details

  1. Home
  2. Paper Details

Carbonic anhydrase inhibition selectively prevents amyloid β neurovascular mitochondrial toxicity.

Author: DebureLudovic, FossatiSilvia, MadambaStephen M, PavlovEvgeny V, PeixotoPablo M, SolesioMaría E, WisniewskiThomas, de LeonMony J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Carbonic anhydrase inhibitors (CAIs) may be a new treatment for Alzheimer's disease (AD). The CAIs methazolamide (MTZ) and acetazolamide (ATZ) were shown to protect neuronal and cerebral vascular cells from amyloid β (Aβ)-induced mitochondrial dysfunction. Both drugs prevented mitochondrial membrane depolarization and H2O2 generation, without affecting intracellular pH or ATP production. Importantly, the drugs did not primarily affect calcium homeostasis.
Paper Details　
Original Abstract of the Article :
Mounting evidence suggests that mitochondrial dysfunction plays a causal role in the etiology and progression of Alzheimer's disease (AD). We recently showed that the carbonic anhydrase inhibitor (CAI) methazolamide (MTZ) prevents amyloid β (Aβ)-mediated onset of apoptosis in the mouse bra...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052473/

データ提供：米国国立医学図書館（NLM）

Carbonic Anhydrase Inhibitors: A New Oasis in the Desert of Alzheimer's Disease

Alzheimer's disease (AD), a devastating neurodegenerative disorder, is like a relentless sandstorm that erodes cognitive function and memory. This research delves into the potential of carbonic anhydrase inhibitors (CAIs) to combat AD by targeting mitochondrial dysfunction, a crucial aspect of the disease's progression.

The researchers explored the effects of methazolamide (MTZ) and acetazolamide (ATZ), two CAIs, on neuronal and vascular cells challenged with amyloid beta (Aβ) – a protein implicated in AD. They discovered that CAIs selectively inhibited Aβ-induced mitochondrial dysfunction without affecting metabolic function, suggesting a targeted approach to protecting mitochondria from the damaging effects of Aβ.

A New Path to Protection

This research offers a promising avenue for treating AD by targeting mitochondrial dysfunction. The CAIs' ability to protect mitochondria from Aβ-induced damage is like finding a hidden oasis in the desert, providing a source of resilience and protection for brain cells. This discovery could lead to the development of new therapeutic strategies for AD, potentially slowing its progression and mitigating its devastating effects.

A Hopeful Horizon for Alzheimer's

This research inspires hope for the future of AD treatment. The potential of CAIs to protect mitochondria from Aβ-induced damage offers a new path to mitigating the devastating effects of this disease. The findings suggest that CAIs, already approved for other medical uses, might be repurposed to combat AD, providing a valuable tool in the fight against this debilitating condition.

Dr. Camel's Conclusion

This research reveals a promising new strategy for combating Alzheimer's disease by targeting mitochondrial dysfunction. Carbonic anhydrase inhibitors (CAIs) show potential to protect mitochondria from the damaging effects of amyloid beta (Aβ), potentially slowing the progression of the disease. This discovery could lead to the development of new and repurposed therapies for AD, offering a glimmer of hope in the desert of this devastating condition.

Date :
  1. Date Completed 2019-10-07
  2. Date Revised 2021-01-09
Further Info :

Pubmed ID

29873184

DOI: Digital Object Identifier

PMC6052473

Related Literature

Article Analysis
・Effects of methazolamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.